Close Menu

NEW YORK (360Dx) – Abreos Biosciences is developing a portfolio of assays that could be used, it said, to determine whether a patient is metabolizing the right dosage of biologic drugs targeting cancers, neurological disorders, and autoimmune diseases.

The San Diego-based firm does not have any assays on the market yet, but if it does get to the point of commercialization, it plans to make them available as laboratory-developed tests, with visions of bringing them to market as point-of-care tests, its CEO Bradley Messmer said.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.